45 results about "Tetrasaccharide" patented technology

The invention discloses a beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H and an application thereof, and belongs to the technical field of functional enzymes. And the amino acid sequence of the beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H is as shown in SEQ ID NO. 3. The invention further discloses the application of the beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H in the preparation of lactose-N-tetrasaccharide. According to the invention, 1, 3-galactosyl transferase Pm beta 3GalT is subjected to mutation modification to obtain a mutant enzyme, and compared with a wild enzyme, the enzyme activity of the mutant enzyme is improved by 157.21% and is obviously improved, and the thermal stability and alkali resistance are also obviously improved. The beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H disclosed by the invention has important theoretical value and application value on the industrial production of LNT (Lipoxystrobin).

The invention belongs to the field of food, particularly relates to a nutritional composition and application thereof in improving immune disorder, and more particularly relates to application of the nutritional composition in preparing food for improving filial generation body inflammatory factor level disorder caused by maternal immune activation. The nutritional composition comprises essential active ingredients shown as the following (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, (ii) a neutral non-fucosylated breast milk oligosaccharide; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the neutral non-fucosylated breast milk oligosaccharide at least comprises lactose-N-neotetraose; in addition, in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 2 '-fucosyllactose is 1: (1-8), and the 2'-fucosyllactose and the lactose-N-neotetraose can achieve a synergistic effect to regulate filial generation immunity.

This invention discloses a high-yield lactyl-3-4 ...5-4-4-4-4-4- N This invention relates to plasmid-free genetically engineered strains of tetrasaccharides and their applications, belonging to the field of microbial genetic engineering. The invention screened strains with higher activity. β -1,3-galactosyltransferase gene PmgalT Computer-aided enzyme function modification was used to achieve a shake-flask yield of 10.05 g / L for the constructed mutant. Subsequently, genome integration was performed... breast Multi-copy integration PmgalT * V27I / V39I / Y147F ‑galE‑galU A plasmid-free strain was constructed, enabling it to grow in shake flasks with lactoyl- N The yield of tetrasaccharides reached 14.4 g / L. Using glucose as the sole carbon source, the highest yield of 68.19 g / L was achieved at 64.5 h; using glycerol as the sole carbon source, the highest yield of 62.88 g / L was achieved at 60.5 h, providing a basis for its industrial production.

The invention belongs to the technical field of biological medicine, and particularly relates to a mycoplasma synoviae culture medium capable of improving strain titer and a preparation method of the mycoplasma synoviae culture medium. The mycoplasma synoviae culture medium comprises a basic culture medium and auxiliary components, the basic culture medium is prepared from HEPES, milk protein hydrolysate, MEM, beef heart extract powder, coenzyme I, 1% phenol red, magnesium sulfate heptahydrate, L-cysteine hydrochloride, lactose-N-tetrasaccharide, disodium clodronate and water; the auxiliary components comprise porcine serum and penicillin. According to the mycoplasma synoviae culture medium obtained by the preparation method, the passage time of the mycoplasma synoviae is shortened, and the strain titer is improved. The inactivated vaccine prepared from the chicken mycoplasma synoviae cultured by the culture medium is good in safety and immunogenicity, can effectively prevent infection of the chicken mycoplasma synoviae, and has a good application prospect.

The present application relates to the technical field of human milk oligosaccharide production, and in particular to a production method of high-purity lacto-N-neotetraose crystal. The production method inoculates the E. coli BL21 star (DE3) BLBRTXST3 strain into a seed liquid culture medium to obtain a seed liquid, then accesses a fermenter in a certain proportion, accurately adjusts the temperature, pH and dissolved oxygen, and adds a final concentration of 0.1 mM IPTG for induction during the product synthesis period, supplements glycerol and lactose in an exponential flow addition mode, inhibits the generation of the by-product lacto-N-neohexaose, significantly improves the yield and purity of lacto-N-neotetraose, and finally obtains a lacto-N-neotetraose crystal product with a purity of ≥98% by combining the optimized crystallization process. The method has the advantages of high yield, high purity, few by-products, controllable process safety, and strong industrialization adaptability.

The invention relates to a beta-carrageenan enzyme mutant AfCarY123A and application thereof, and belongs to the technical field of functional enzymes, and the amino acid sequence of the mutant AfCarY123A is as shown in SEQ ID NO. 1. The invention further provides an enzyme preparation containing the mutant AfCarY123A, a recombinant expression vector containing a gene for coding the mutant AfCarY123A, a recombinant engineering bacterium and application of the recombinant expression vector and the recombinant engineering bacterium. The mutants can be used for degrading kappa-carrageenan into kappa-neocarrageenan tetrasaccharide, kappa-neocarrageenan hexasaccharide, kappa-neocarrageenan octasaccharide, kappa-neocarrageenan decasaccharide and kappa-neocarrageenan dodecasaccharide.

The invention relates to the technical field of cosmetics, in particular to acer truncatum moisturizing pre-makeup cream and a preparation method thereof. The acer truncatum moisturizing makeup pre-cream is prepared from the following components in parts by weight: acer truncatum seed oil, cosmetic-grade purified water, cetyl PEG / PPG-10 / 1 polydimethylsiloxane, polydimethylsiloxane, isononyl isononanoate, synthetic wax, microcrystalline wax, glycerol, 1, 2, 4-trimethyl-1, 3-pentanediol monoisobutyrate, propylene glycol monobutyl ether, propylene glycol monobutyl ether, propylene glycol monobutyl ether, propylene glycol monobutyl ether, propylene glycol monobutyl ether, propylene glycol the mannuronic acid tetrasaccharide micro-capsule is coated with 1, 3-propylene glycol / caprylyl glycol / ethylhexylglycerin, butanediol, sodium chloride, a sodium hyaluronate cross-linked polymer and temperature-sensitive polyglycerol-10 stearate. The acer truncatum seed oil containing 6% of nervonic acid serves as core lipid, temperature-sensitive type microencapsulated mannuronic acid tetrasaccharide and response type composite microcapsules are compounded, a'instant moisturizing-delayed moisturizing-barrier repairing 'triple synergistic system is constructed, the defects of a traditional technology are overcome, and the requirements of consumers for long-acting, efficient and mild pre-makeup care are met.

The present invention provides protected tetrasaccharides, their process of preparation and their use as common scaffold precursors in the synthesis of oligosaccharides representing segments of the O-antigens from diverse S. flexneri serotypes, comprising for example SF2a, SF3a, SF2b, SF1b, SFX and / or SFY.

The application provides a genetically engineered bacterium for producing lactose-N-neotetraose, a construction method and application thereof. The genetically engineered bacterium satisfies the following conditions: (1) exogenous expression of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase; (2) overexpression of galactoside permease and UDP-galactose-4-epimerase; and (3) no expression or weakened expression of setA transporter protein. The applicant of the application finds through research that exogenous introduction of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase in the genetically engineered bacterium, enhancement of the expression amount of galactoside permease and UDP-galactose-4-epimerase in the genome, and reduction of the expression amount of setA transporter protein can effectively reduce the residual amount of LNT II in the LNnT synthesis pathway and improve the fermentation yield of LNnT.

The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.

The invention discloses a preparation method of low-viscosity polydextrose, and belongs to the technical field of polydextrose preparation. Carrying out multi-stage polymerization reaction on the saccharified liquid, and then refining to obtain low-viscosity polydextrose; the saccharification liquid comprises 10 wt% of glucose, 40 wt% of maltose, 40 wt% of maltotriose, and 10 wt% of tetrasaccharide or above; the multi-stage polymerization reaction specifically comprises the following steps: adding 1wt% of citric acid and 1wt% of sorbitol into the saccharified liquid, and reacting under a high-temperature condition until the content of glucose is 1t; 2 wt%; glucose is supplemented, the adding amount is 10-30 wt% of that of the previous system, and the reaction continues until the glucose content is 1t; 2 wt%; supplementing 20-40wt% of glucose, and continuing the reaction until the content of the glucose is 1t; and 2 wt%. Starch can be adopted as a raw material, and pigment accumulation is reduced by adopting a specific preparation method; meanwhile, the viscosity of the polydextrose is reduced by controlling the size of a molecular chain.

The invention provides a preparation method of an antibody conjugate containing an sLeX tetrasaccharide structure, which comprises the following steps: S1, sequentially adding Endo S2 enzyme and alpha-L-fucosidase into a target antibody, and respectively analyzing glycosylation to avoid modification site conflict or carbohydrate chain structure interference; s2, adding the accurately represented antibody in the S1, B4GalT1 and UDP-Gal into a Tris-HCl system containing Mn < 2 + >, and incubating to obtain a reaction solution I; s3, the reaction liquid I, ST3Gal3, CMP-Neu5Ac and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is carried out; adding CMP-N-acyl neuraminic acid phosphodiesterase for reaction, and purifying Protein A to obtain a purified antibody I; s4, the purified antibody I, alpha1, 3 FucT-2HR, GDP-Fuc and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is performed; and purifying Protein A to obtain a target product. According to the modified antibody obtained by the invention, while the targeting property is improved, the binding affinity of the antibody and a tumor cell surface antigen can be enhanced, so that the immune blocking activity of the antibody is further enhanced, and dual improvement of the targeting property and the activity is realized.

The application provides a hybridoma cell strain secreting a monoclonal antibody against a alginate mannuronic acid tetrasaccharide epitope, a monoclonal antibody and application. In order to enhance the immunogenicity of the mannuronic acid tetrasaccharide, a glycoconjugate KLH-1 is used as an immunogen to inject and immunize a mouse, so that the mouse is stimulated to produce a specific immune response against the mannuronic acid tetrasaccharide epitope, then spleen cells of the immunized mouse are fused with myeloma cells, and after screening, an initial hybridoma cell strain is obtained; then after subcloning and specific screening, a hybridoma cell strain capable of stably secreting a monoclonal antibody of the target mannuronic acid tetrasaccharide epitope in alginate is obtained, and a monoclonal ascites antibody is further obtained. The monoclonal ascites antibody shows specific recognition and combination ability for pseudomonas aeruginosa, and the combination activity is related to the expression level of alginate on the surface of the bacteria. Therefore, the monoclonal ascites antibody can be used as a precise detection and diagnosis tool for pseudomonas aeruginosa, and can also be applied to the antibacterial treatment of pseudomonas aeruginosa infection.

The present invention provides a fucosylated human milk oligosaccharide (HMO) for use in improving brain development and / or vision development in a subject wherein: a) the fucosylated HMO is lactose-N-fucopentasaccharide-I (LNFP-I) and the subject is an infant of up to 12 months of age; and / or b) the fucosylated HMO is A-tetrasaccharide, wherein the individual is an infant, toddler or child.

The present application relates to a kind of beta-carrageenanase mutant AfCarY123A and its application, belong to functional enzyme technical field, the amino acid sequence of the mutant AfCarY123A as shown in SEQ ID NO.1.The present application also provides enzyme preparation containing the mutant AfCarY123A, and the recombinant expression vector containing the gene encoding the mutant AfCarY123A, recombinant engineering bacteria and its application, the mutant can κ-carrageenan is degraded into κ-new carrageenan tetrasaccharide, κ-new carrageenan hexose, κ-new carrageenan octasaccharide, κ-new carrageenan decasaccharide and κ-new carrageenan twelve saccharide.

The present application provides human milk oligosaccharides capable of improving the bioavailability of mineral zinc and applications thereof. Specifically, the present application provides the use of lacto-N-neotetraose (LNnT) in the preparation of products capable of improving the bioavailability of mineral zinc. In the present application, lacto-N-neotetraose is used to improve the bioavailability of mineral zinc, especially for individuals lacking zinc, which can significantly improve the retention of zinc in the body and promote the digestion and absorption of zinc by individuals.

The present disclosure relates to a non-therapeutic use of a human milk oligosaccharide (HMO) selected from 3'-sialyllacto-N-tetraose (LSTa), 6'-sialyllacto-N-neotetraose (LSTc) and 3'-sialyl- 3-fucosyllactose (FSL), or a combination thereof, in supporting or improving one or more of brain health, immune system health, gut health, and metabolic health, in a subject, optionally by increasing the production of one or more metabolites selected from the group consisting of of pyridoxine, pyridoxamine, nicotinic acid, N-acetyl-L-glycine, sarcosine, N-acetyl-L-glutamine, N- acetyl-L-aspartic acid, trigonelline, trans-4-hydroxyproline, 3-hydroxybutyric acid (BHB), 4- hydroxybenzoic acid, and N-acetyl-L-tryptophan, in the gastrointestinal tract of the subject.

The present invention provides variants of a beta-1, 3-N-acetylglucosamino transferase polypeptide, which variants have a higher substrate specificity for lactose than for milk-N-neotetraose as compared to Neisseria meningitidis LgtA, and also provides microbial cells having such variants of a beta-1, 3-N-acetylglucosamino transferase polypeptide, which variants have a higher substrate specificity for lactose than for milk-N-neotetraose as compared to Neisseria meningitidis LgtA, in particular to a mutant of a beta-1, 3-N-acetylglucosamino transferase polypeptide, in particular to a mutant of a beta-1, 3-N-acetylglucosamino transferase polypeptide, and a mutant of a beta-1, 3-N-acetylglucosamino transferase polypeptide. And their use in the production of oligosaccharides of interest containing N-acetylglucosamine moieties.

The present invention aims to provide a saccharide composition suitable for a cyclic-tetrasaccharide-containing starch syrup which has low viscosity, low water activity, low coloration property, and low calorie content, and which is unlikely to cause precipitation of crystals of saccharides during storage, and to provide a use of the composition and a production method for the composition. The object is achieved by providing a cyclic-tetrasaccharide-containing saccharide composition having the following characteristics (1) to (3): (1) the saccharide composition includes a branched cyclic tetrasaccharide in addition to the cyclic tetrasaccharide, wherein the content of the cyclic tetrasaccharide with respect to the total solid content of the saccharide composition obtained by allowing glucoamylase and α-glucosidase to act on the above saccharide composition is 38% by mass or higher, on a dry solid basis; (2) the ratio of α-1,4-linked glucose in the total glucose residues constituting the saccharide composition in methylation analysis is over 9% and 15% or lower, and (3) the ratio of α-1,4,6-linked glucose in the total glucose residues constituting the saccharide composition in methylation analysis is less than 6%; and providing a use of the composition and a production method for the composition.

The present disclosure is directed to the generation and use of a synthetic tetrasaccharide designed based on a portion of a mycobacterial polar glycolipid as a vaccine antigen to limit or prevent tuberculosis infections.

The invention discloses recombinant Escherichia coli with high yield of lactose-N-tetrasaccharide and application of the recombinant Escherichia coli, gloA and nagB genes on a genome of the recombinant Escherichia coli are knocked out, an lgtA2 gene and a SewbdO gene are integrated on the genome of the recombinant Escherichia coli, and compared with a recombinant Escherichia coli strain without the gloA and nagB genes, the fermentation production of LNT by the recombinant Escherichia coli strain without the gloA and nagB genes is remarkably improved; especially, after the galE gene is integrated on the genome, the lactose-N-tetrasaccharide can be produced by fermentation in a fermentation culture medium without glycerol, the yield of the lactose-N-tetrasaccharide is high, the intermediate metabolite LNTII is low, and industrial popularization and application are facilitated.

The invention discloses a synthetic method and application of antrodia camphorata galactomannan oligosaccharide and polysaccharide, and belongs to the field of carbohydrate chemistry and medicinal chemistry. According to the method, five tetrasaccharide building blocks are used as synthons, the construction efficiency of antrodia camphorata galactose 1, 2-cis-glucosidic bonds is improved through remote participation of galactose 4-position benzoyl, and octasaccharide, hexadecanose and tetracosanose of antrodia camphorata are stereoselectively constructed through [4 + 4], [8 + 8] and [16 + 8] glycosylation strategies by utilizing the method; the obtained oligosaccharides and polysaccharides are subjected to deprotection to obtain six antrodia camphorata galactomannan oligosaccharides and polysaccharides with definite structures, single components and anti-inflammatory activity. A cellular immune experiment shows that the oligosaccharide and the polysaccharide can inhibit LPS (lipopolysaccharide)-induced mouse macrophage RAW 264.7 inflammatory response, and have potential application in anti-inflammatory drugs; meanwhile, the antigens are good antigens of antrodia camphorata sugar vaccines and can be developed into sugar vaccines or sugar drugs.

The invention relates to recombinant escherichia coli for synthesizing sialic acid lactose-N-tetrasaccharide c as well as a construction method and application of the recombinant escherichia coli. The supply of a precursor CMP-Neu5Ac of the recombinant escherichia coli is optimized by adding a new synthesis route; alpha 2, 6-sialyltransferase with high efficiency and high specificity is screened and integrated into an escherichia coli BL21 (DE3) genome, so that the yield of sialyllactose-N-tetrasaccharide c is further increased, and accumulation of precursors LNnT and LNTII and a byproduct 6 '-SL is reduced; by adding the sugar efflux transporter gene, the inhibition effect caused by intracellular accumulation of high-concentration sugar products is reduced. The recombinant escherichia coli is used for culture and fermentation, high-yield sialic acid lactose-N-tetrasaccharide c can be synthesized, and the proportion of the obtained product sialic acid lactose-N-tetrasaccharide c in total HMO is further increased.

The invention discloses a bioengineering method for efficiently synthesizing lactoyl-N-tetrasaccharide, and belongs to the field of biotechnology and food fermentation engineering. The method comprises the following steps: firstly, carrying out combined regulation on lgtA, wbgO, galE, galT and galK genes in a lactoyl-N-tetrasaccharide synthesis pathway to optimize the expression dose of pathway genes, then, sequentially knocking out collateral metabolic pathway genes lacZ, wecB, ugd, nagB, pfkA, gloA and setA on a chromosome of escherichia coli BL21 (DE3) by utilizing a CRISPR-Cas9 technology, and respectively integrating a nucleotide glycometabolism key gene cluster galE-galT-galK at a yeeJ site, so as to obtain the lactoyl-N-tetrasaccharide synthesis pathway. A core glycosyl transferase gene lgtA-wbgO is integrated at a caiB site, and finally an engineering strain capable of efficiently synthesizing lactoyl-N-tetrasaccharide is constructed. The engineering bacterium can be used for realizing efficient synthesis of lactoyl-N-tetrasaccharide in a restrictive glycerol culture medium by taking lactose as a substrate. Under a shake-flask culture condition, the ability of the escherichia coli for synthesizing the lactoyl-N-tetrasaccharide is improved from 3.41 g / L to 11.15 g / L, and the yield of the lactoyl-N-tetrasaccharide reaches 125.35 g / L in fed-batch culture of a 3 L fermentation tank.

The present application relates to a kind of recombinant escherichia coli of synthetic sialyllactose-N-tetrasaccharide c and its construction method and application, by adding new synthetic pathway, the supply of its precursor CMP-Neu5Ac is optimized;By screening high-efficiency, specific strong alpha2,6-sialyltransferase, and it is integrated into escherichia coli BL21 (DE3) genome, further improve the yield of sialyllactose-N-tetrasaccharide c, reduce the accumulation of precursor LNnT, LNTII and by-product 6'-SL;By adding sugar efflux transporter gene, reduce the inhibitory effect brought by intracellular accumulation of high-concentration sugar product.Synthetic sialyllactose-N-tetrasaccharide c of high yield can be obtained by culturing and fermenting recombinant escherichia coli, and further improve the proportion of the obtained product sialyllactose-N-tetrasaccharide c in total HMO.

The application discloses a synthesis method and application of Ganoderma annularis galactomannan oligosaccharide and polysaccharide, and belongs to the field of sugar chemistry and medicinal chemistry. Five tetrasaccharide building blocks are used as synthesis subunits, the construction efficiency of Ganoderma annularis galactose 1,2-cis glycosidic bond is improved through remote participation of benzoyl at the 4th position of galactose, and through [4+4], [8+8] and [16+8] glycosylation strategies, Ganoderma annularis octasaccharide, hexadecasaccharide and twenty-four saccharide are stereoselectively constructed; the obtained oligosaccharide and polysaccharide are deprotected to obtain six Ganoderma annularis galactomannan oligosaccharides and polysaccharides with anti-inflammatory activity, which have definite structures and single components. Through cell immunity experiments, it is found that the above oligosaccharide and polysaccharide can inhibit the inflammatory reaction of LPS-induced mouse macrophage RAW 264.7, has potential application in anti-inflammatory drugs, and is also a good antigen of Ganoderma annularis sugar vaccine, and can be developed into a sugar vaccine or a sugar drug.

The present invention relates to nutritional compositions, products comprising them and uses thereof. The nutritional composition comprises lactose-N-neotetraose, and choline and / or edible derivatives thereof, wherein the ratio of the lactose-N-neotetraose to the total choline mass converted from the choline and the edible derivatives thereof is 0.1: 1 to 10: 1. The nutritional composition can synergistically regulate and control the nerve function of the organism.

The invention discloses Escherichia coli LNT I-2 and a method for stably generating lactose-N-tetrasaccharide on a large scale by using the Escherichia coli LNT I-2. The preservation number of the Escherichia coli LNT I-2 is CCTCC NO: M 20251742, the Escherichia coli LNT I-2 is classified and named as Escherichia coli LNT I-2, the preservation date is July 31, 2025, the Escherichia coli LNT I-2 can utilize a fermentation culture medium without glycerol or without glycerol as a supplementary material to stably ferment and produce LNT at high yield, lactose hydrolysate can be adopted as an inducer to induce synthesis of a product-lactose-N-tetrasaccharide, and the yield of the LNT is increased. The method meets the requirements of green and efficient synthesis of the LNT, and is beneficial to popularization of industrial large-scale microbial fermentation production of the LNT.

The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.

Composition or association of compounds comprising: a) the active principle docosahexaenoic acid DHA (C22:6 ω-3 C22H32O2 MW 328.488) mixed with all or in part, with: b) hyaluronic acid HA4 tetrasaccharide (C28H44N2O23 MW 776) in nanoparticles c) β-caryophyllene βCP (C15H24 MW 204.35), d) furanoeudesma-1,3-diene FE (C15H18O MW 214.30), e) β-boswellic acid PBA (C30H48O3 MW 456.7). preferably for use in the treatment of nervous diseases in particular neurodegenerative diseases, method for the preparation of such composition or association of compounds and uses thereof.